Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
Maria Gavriatopoulou, Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Evangelos Eleutherakis‐Papaiakovou, Αθανάσιος Παπαθεοδώρου, Nikolaos Kanellias, Magdalini Migkou, Despina Fotiou, Ioanna Dialoupi, Μαρία Ρούσσου, Nikoletta‐Aikaterini Kokkali, Efstathios Kastritis, Meletios Α. Dimopoulos
Abstract
Despite the continuous introduction of novel agents in the upfront treatment of multiple myeloma (MM), autologous stem cell transplantation (ASCT) remains a cardinal approach for fit patients 1 . Both the durability and depth of response post ASCT have been recognized as important prognostic factors 2 . Consolidation therapy further improves depth of response. However, there is no consensus on the optimal regimen. Minimal residual disease (MRD) negativity after treatment for newly diagnosed MM patients (NDMM) represents a strong prognostic factor 3 . Therefore, MRD could guide treatment decisions. Βone health is of high importance for NDMM patients as they are at high risk of developing skeletal-related events (SREs) that impair quality of life 4 . Taking all the above factors into consideration, the aim of this prospective study was to evaluate the efficacy, the safety, and the effect on bone metabolism of carfilzomib, lenalidomide, and dexamethasone (KRd) as a consolidation regimen in transplant-eligible patients who had not achieved MRD negativity following ASCT.